You are here

Janssen to Discontinue Hepatitis C Development Program

Johnson & Johnson unit will focus on hepatitis B instead

Janssen Sciences Ireland UC will discontinue further development of the investigational hepatitis C virus treatment regimen JNJ-4178, a combination of three direct acting antivirals—AL-335, odalasvir, and simeprevir.

Ongoing phase 2 studies with JNJ-4178 will be completed as planned, but there will be no additional development thereafter. This “strategic decision” was made “in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C,” the company said.

"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists. Our scientists are energized by this challenge and our research ambition is to achieve a functional cure of hepatitis B, which affects over a quarter of a billion people globally," said Lawrence M. Blatt, PhD, Global Therapeutic Area Head, Infectious Disease Therapeutics, Janssen.

Janssen pioneered the advancement of the first innovations in hepatitis C for nearly a decade when it codeveloped telaprevir, a first-in-class protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus. In collaboration with Medivir AB, Janssen subsequently developed and launched the second generation protease inhibitor simeprevir (Olysio).

Sources: Janssen; September 11, 2017; Medivir; September 11, 2017.

More Headlines

So far, 20,000 people have been hospitalized
In interim assessment of vaccine effectiveness, young children do better
Novel clinical trial endpoint, metastasis-free survival, was used in evaluation
Quick testing option may help reduce CT scans, radiation exposure
U.S. health care spending to climb 5.3% in 2018, agency predicts
FDA permits marketing of Viz.AI Contact to speed treatment
Did other treatments confound the results?
Senator’s investigation found a “lack of transparency” surrounding the donations